Goldman lifts Gilead’s target, keeps it chilly

Goldman says “nice, but not that nice”

Goldman Sachs nudged its price target on Gilead Sciences up to $130 from $125, while sticking with a neutral rating. Translation: the bank sees a little more value here, but not enough to start tossing confetti.

Why this matters to your portfolio

For investors, the interesting part isn’t the tiny target raise — it’s the message underneath it. Gilead is sitting in that awkward middle zone where the numbers look solid, the pipeline has stories to tell, and yet the stock still needs a bigger catalyst to really break out of the waiting room.

The article also notes a few moving parts around the name:

• Gilead slightly beat quarterly expectations with $1.86 EPS vs. $1.83 expected and $7.93 billion in revenue vs. $7.68 billion expected
• Management guided fiscal 2026 EPS to 8.45–8.85, above analyst estimates around 7.95
• The Arcellx acquisition got regulatory approvals, though the tender offer was extended
• Insiders have been selling shares, even as big institutions reportedly added to positions

The real investor read

This is less “all clear, buy now” and more “the story is getting better, but patience still required.” Analysts are warming up to Gilead’s setup, but they’re not exactly racing to the altar. With earnings around the corner, the stock may be stuck in one of those classic biotech moments where every little update gets treated like a mood ring.

Big picture: Gilead is getting incremental love, not a full-blown re-rating — which means the next real move probably needs more than just a polite price-target tweak.